Loading…
← CockpitCompetitor Analysis › 688553.SS Sichuan Huiyu Pharmaceutical Co. Ltd. Class AOpen in the cockpit ↗

Sichuan Huiyu Pharmaceutical Co. Ltd. Class A688553.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Sichuan-based pharmaceutical manufacturer selling drugs in China.

Momentum weak 39
Mkt cap
$904M
US dollars, full cap
Free float
70%
of shares outstanding
$/day
$16.4M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-2.3 pp
WACC 9.1%
Hurdle
+25 pp
Req g minus delivered
Next earnings
159 days
26 Apr 2027
Close · CNYCN¥9.78
1D-3.4%
1W-13.3%
1M-10.4%
3M-21.1%
6M-27.9%
YTD-18.6%
1Y-32.3%
ATR %5.6%
52w lowhigh43.6% off high

What Sichuan Huiyu Pharmaceutical does

Sichuan-based pharmaceutical manufacturer selling drugs in China.

Where it sits in the supply chain

  • Pharmaceuticals
  • Generics/specialty

Moat: none

Headquarters: Sichuan, China · Employees: 1,366

Sichuan Huiyu Pharmaceutical at a glance

Size Sichuan Huiyu Pharmaceutical (688553.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $904M, the 2353rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.78 on 18 Nov 2026.

Performance Over six months the shares fell 27.9%, against -16.9% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 20 in its peer set.

Growth Revenue grew 14.0% over the last twelve months (peer median +2.1%); the operating margin is 7.1% (peer median 6.7%).

Valuation It trades at 3.5× enterprise value to sales against a peer median of 3.9× (9th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is +25 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.3 points below its cost of capital (9.1% WACC).

Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 84688553.SS 73
Six months, rebased to 100: Sichuan Huiyu Pharmaceutical against the median of its 20 peers (local-currency closes).

Sichuan Huiyu Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.12BCN¥996MCN¥1.09BCN¥924MCN¥1.49B
Revenue growth—-9%+18%-38%—
Gross profitCN¥888MCN¥737MCN¥849MCN¥759MCN¥1.28B
EBITDAn/aCN¥110MCN¥143MCN¥69.9MCN¥185M
Net incomeCN¥129M-CN¥25.0MCN¥325MCN¥140MCN¥249M
Free cash flowCN¥101MCN¥26.4MCN¥135M-CN¥194M-CN¥220M
Capital expenditureCN¥62.8MCN¥105MCN¥128MCN¥297MCN¥462M
Total debtCN¥725MCN¥648MCN¥594MCN¥436MCN¥55.0M

Quarterly statements and history in the cockpit →

Sichuan Huiyu Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%2595AKTSIMTX000597MLTX1795300401039200688177600252600422SANOFICONRPHARM0061206007716035382005688553.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Sichuan Huiyu Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%0×20×40×60×2595AKTSIMTX0005971795300401039200600422SANOFICONR006120688553.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sichuan Huiyu Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%0005971795300401039200600252002437SANOFICONRPHARM600771603538STAR2005688553.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sichuan Huiyu Pharmaceutical is the large dot.

Sichuan Huiyu Pharmaceutical competitors and peer comparison

How Sichuan Huiyu Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sichuan Huiyu Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure688553.SSPeer medianRank in peer set
1-month return-10.4%-9.1%9th lowest of 21
6-month return-27.9%-16.9%7th lowest of 20
Distance from 52-week high-43.6%-44.2%10th highest of 21
Revenue growth (TTM)+14.0%+2.1%8th highest of 19
Operating margin7.1%6.7%10th highest of 19
EV / Sales3.5×3.9×9th cheapest of 19
Growth the price implies (Req g, 7 yrs)19.4%8.4%2nd most demanding of 13
Growth delivered (Del g)-6.0%+6.3%3rd lowest of 13
Hurdle (Req g minus delivered)+25.4 pp-0.8 pp2nd most demanding of 13
ROIC minus cost of capital-2.3 pp-0.2 pp6th lowest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%3.5×19.4%-6.0%
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%55.9×n/an/a
Aktis Oncology AKTSUnited States$895M-15%+337%-837%33.4×n/an/a
Immatics IMTXUnited States$913M-46%-44%-589%8.5×n/an/a
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%0.9×-7.6%-0.7%
MoonLake Immunotherapeutics MLTXUnited States$918M-37%n/an/an/an/an/a
Lotus Pharmaceutical 1795.TWTaiwan$921M-37%+67%21%2.6×-3.7%+13.8%
Zhejiang Garden Biopharmaceutical 300401.SZChina$922M-14%+2%24%5.2×9.1%+13.4%
Oscotec 039200.KSSouth Korea$923M-32%+510%59%7.5×-10.2%+18.1%
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
Bio-Thera Solutions 688177.SSChina$929M-23%+24%-44%6.5×n/an/a
Guangxi Wuzhou Zhongheng 600252.SSChina$936M-10%-43%-42%4.5×10.3%-13.7%
KPC Pharmaceuticals 600422.SSChina$940M-6%-41%-10%1.8×n/an/a
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%2.8×7.7%-6.9%
Sanofi Consumer Healthcare India SANOFICONR.NSIndia$869M-26%+23%36%8.3×17.7%+22.7%
Pharming PHARM.ASNetherlands$867M-6%+2%9%2.2×2.4%+12.4%
SK Discovery 006120.KSSouth Korea$866M+25%+24%3%0.8×n/an/a
GuangYuYuan Chinese Herbal Medicine 600771.SSChina$866M-26%-6%5%4.1×31.7%+4.2%
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%3.8×11.6%+4.9%
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%2.0×17.6%+7.8%
SSY 2005.HKHong Kong$948M+8%-4%12%2.2×2.3%-0.5%

Questions

Which companies are Sichuan Huiyu Pharmaceutical's closest peers?
The cockpit's peer set: Genfleet Therapeutics (Shanghai) (2595.HK), Aktis Oncology (AKTS), Immatics (IMTX), Northeast Pharmaceutical (000597.SZ), MoonLake Immunotherapeutics (MLTX), Lotus Pharmaceutical (1795.TW), Zhejiang Garden Biopharmaceutical (300401.SZ), Oscotec (039200.KS).
Is Sichuan Huiyu Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 3.5× against a peer median of 3.9×, 9th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is +25 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Sichuan Huiyu Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -27.9% against -16.9% for the median peer; over one year -32.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.